RxDoctor Payments Data

Katie Nacpil, NP

Gerontology · Fort Worth, TXNPI 1184267221

Payments from drug & device makers

$3,959in general payments, 2019–2025

Across 107 payments — averaging $37.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Teleflex LLC$768
  • Astellas Pharma US Inc$208
  • Boston Scientific$207
  • Sumitomo Pharma America, Inc.$199
  • Verity Pharmaceuticals Inc.$178
  • plus $971 from 19 others

What the payments were for

  • Travel & lodging$1,49538%
  • Food & beverage$2,36460%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,959 in reported general payments places this provider in the 90th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$80,946
Medicare patients
499
Services billed
1,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron338$244,064
GemtesaVibegron42$39,054
Mirabegron ErMirabegron45$35,529
Methenamine Hippurate111$11,157
Estradiol86$6,428
Tamsulosin Hcl249$4,032
Alfuzosin Hcl ErAlfuzosin Hcl154$3,924
Finasteride178$2,427
Testosterone Cypionate54$2,185
Oxybutynin Chloride ErOxybutynin Chloride106$1,631
NitrofurantoinNitrofurantoin Macrocrystal54$1,180
Potassium Citrate ErPotassium Citrate15$1,155
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav109$1,122
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$883
Solifenacin Succinate30$789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$208$244,064338 claims
Sumitomo Pharma America, Inc.Gemtesa$199$39,05442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 gerontology providers in Texas.

Other gerontology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →